Compare BEDU & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEDU | GNTA |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | United Kingdom | Italy |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.0M | 39.4M |
| IPO Year | 2017 | 2021 |
| Metric | BEDU | GNTA |
|---|---|---|
| Price | $2.19 | $1.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.8K | ★ 122.3K |
| Earning Date | 01-23-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $224,321,752.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.35 | $1.35 |
| 52 Week High | $2.28 | $10.00 |
| Indicator | BEDU | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 57.57 | 42.36 |
| Support Level | $2.14 | $1.80 |
| Resistance Level | $2.22 | $2.20 |
| Average True Range (ATR) | 0.03 | 0.23 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 43.75 | 66.67 |
Bright Scholar Education Holdings Ltd operates as an education service provider. It is engaged in the provision of education services, including complementary education services, operation services for domestic schools, and education programs and services including independent schools and colleges in United Kingdom and the United States. It nearly eight overseas school located in the United Kingdom and the United States. It has three reportable segments, including Overseas Schools, Complementary Education Services, and K-12 Operation Services. Key revenue is generated from Overseas Schools. From a geographical perspective: Key revenue is generated from China following UK, U.S., Canada and Singapore.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.